Large reference laboratories with their eyes on the fast-growing esoteric testing market are scrambling to shore up their positions in genomics. In doing so, they are jumping into exclusive deals with companies that have programs for discovering disease-associated molecular markers with such vigor that in one recent 10-day period the nation's two largest laboratories each issued two press releases about a total of four exclusive deals they'd done.
The deals aim to give the laboratories, which still obtain most of their revenues from traditional, slow-growth in vitro diagnostics...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?